公开(公告)号：US10787453B2

公开(公告)日：2020-09-29

申请号：US15950528

申请日：2018-04-11

申请人： Konstantin Petrukhin ,  Christopher Cioffi ,  Graham Johnson ,  Nicoleta Dobri ,  Emily Freeman ,  Ping Chen ,  Michael Conlon ,  Lei Zhu

发明人： Konstantin Petrukhin ,  Christopher Cioffi ,  Graham Johnson ,  Nicoleta Dobri ,  Emily Freeman ,  Ping Chen ,  Michael Conlon ,  Lei Zhu

IPC分类号： A61K31/407 ,  A61K31/4162 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/4353 ,  A61K31/44 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5365 ,  A61K31/55 ,  C07D487/04 ,  C07D403/04 ,  C07D403/12 ,  C07D401/12 ,  C07D403/06 ,  C07D471/04 ,  C07D498/04 ,  C07D209/52 ,  C07D519/00

摘要： The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.

公开(公告)号：US10786488B2

公开(公告)日：2020-09-29

申请号：US16479997

申请日：2018-01-23

申请人： MERCK SHARP & DOHME CORP.

发明人： Tao Yu ,  John A. McCauley ,  Alan Whitehead ,  James M. Apgar ,  Izzat T. Raheem ,  Guizhen Dong ,  Sherman T. Waddell ,  Hong Li

IPC分类号： A61K31/4375 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/47 ,  A61K31/506 ,  A61K31/5365 ,  A61K31/675 ,  A61K31/7068 ,  A61K31/7076 ,  C07D491/147

摘要： The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

公开(公告)号：US10738062B2

公开(公告)日：2020-08-11

申请号：US16326043

申请日：2017-08-14

申请人： Merck Sharp & Dohme Corp.

发明人： Wensheng Yu ,  Joseph A. Kozlowski ,  Ling Tong ,  Craig A. Coburn ,  Bin Hu ,  Bin Zhong ,  Jinglai Hao ,  Dahai Wang

IPC分类号： C07D498/04 ,  A61K45/06 ,  A61K31/496 ,  A61K31/5365 ,  A61P31/14

摘要： The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

公开(公告)号：US20200237770A1

公开(公告)日：2020-07-30

申请号：US16843946

申请日：2020-04-09

申请人： The Global Alliance for TB Drug Development, Inc.

发明人： Khisimuzi Mdluli ,  Cari M. Mendel ,  Eric Nuemberger

IPC分类号： A61K31/5377 ,  C07D241/24 ,  C07D215/227 ,  C07D263/20 ,  C07D498/04 ,  A61P31/04 ,  A61K31/5365 ,  A61K31/4965 ,  A61K31/47

摘要： The present invention relates to therapeutic combinations of anti-bacterial agents linezolid, bedaquiline and pretomanid, and optionally with pyrazinamide, in a short-course oral dosage regimen for the treatment of tuberculosis.

公开(公告)号：US20200147092A1

公开(公告)日：2020-05-14

申请号：US16631859

申请日：2018-07-19

申请人： ViiV Healthcare Company

发明人： Michael ABOUD ,  Pedro CAHN ,  Thomas LAUGHERY ,  Dominique J. LIMET ,  John C. POTTAGE ,  Kimberly Y. SMITH

IPC分类号： A61K31/5365 ,  A61P31/18 ,  A61K31/513 ,  A61K9/20

摘要： Disclosed are methods for treating human immunodeficiency virus (HIV) or AIDS in a human subject using only two antiretroviral drugs, the subject being virologically suppressed and having previously followed a treatment regimen including at least three antiretroviral drugs.

公开(公告)号：US10604568B2

公开(公告)日：2020-03-31

申请号：US14904011

申请日：2014-07-30

申请人： BioNTech AG ,  Astellas Pharma Inc. ,  TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH

发明人： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC分类号： A61K39/395 ,  A61K47/68 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  C07K16/28 ,  G01N33/574 ,  A61K33/24 ,  A61N5/10 ,  C07K16/30 ,  A61K39/00

摘要： The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

公开(公告)号：US20200046634A1

公开(公告)日：2020-02-13

申请号：US16389396

申请日：2019-04-19

申请人： ImmunoGen, Inc.

发明人： Kelli RUNNING ,  Robert A. MASTICO ,  James J. O'LEARY ,  Olga AB ,  Beni WOLF

IPC分类号： A61K9/00 ,  A61K45/06 ,  A61K31/5365 ,  C07K16/28 ,  A61K31/573 ,  A61K47/68

摘要： Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.

公开(公告)号：US20200038389A1

公开(公告)日：2020-02-06

申请号：US16512166

申请日：2019-07-15

申请人： Gilead Sciences, Inc.

发明人： Laura Elizabeth Bauer ,  Anna Chiu ,  Eric M. Gorman ,  Andrew Stephen Mulato ,  Martin Sunkwang Rhee ,  Charles William Rowe ,  Scott P. Sellers ,  Dimitrios Stefanidis ,  Winston C. Tse ,  Stephen R. Yant

IPC分类号： A61K31/4439 ,  A61P31/18 ,  A61K31/685 ,  A61K31/536 ,  A61K31/5365 ,  A61K31/34 ,  A61K31/4418 ,  A61K9/00 ,  A61K9/48

摘要： The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

公开(公告)号：US20190350853A1

公开(公告)日：2019-11-21

申请号：US15735118

申请日：2016-06-15

申请人： University of Washington

发明人： Rodney J.Y. Ho ,  Jennifer Iwamoto

IPC分类号： A61K9/127 ,  A61K47/24 ,  A61K9/14 ,  A61K9/51 ,  A61K31/427 ,  A61K31/513 ,  A61K31/536 ,  A61K31/5365 ,  A61K31/675 ,  A61K31/7072

摘要： Provided are multi-drug lipid nanoparticles that stably incorporate multiple small molecule drugs with divergent hydrophobic and water solubility characteristics and related methods of making and using the same, The disclosed compositions and methods provide for enhanced stability of lipid nanoparticle drug formulations that can reliably provide drugs addressing different mechanistic targets with prolonged presence in the body for more efficacious treatment and avoidance of single drug resistance.

公开(公告)号：US10449259B2

公开(公告)日：2019-10-22

申请号：US15764188

申请日：2016-09-30

申请人： Cornell University

发明人： Shek Hang Benedict Law ,  Ching-Hsuan Tung ,  Vanessa Bellat

IPC分类号： A61K47/69 ,  A61K47/42 ,  A61K9/70 ,  A61K47/65 ,  A61K47/60 ,  A61P35/00 ,  A61K38/06 ,  A61K38/20 ,  A61K38/21 ,  A61K38/50 ,  A61K31/167 ,  A61K31/704 ,  A61K9/00 ,  A61K31/5365

摘要： The disclosure provides compositions comprising peptide-based nanofiber precursors and methods of using the same to inhibit cancerous cell growth and/or to deliver therapeutic or diagnostic agents to cells, e.g., cancerous cells. The compositions of the present technology include peptide-based nanofiber precursors as well as carrier complexes comprising a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor. Also provided herein are methods for delivering a therapeutic or diagnostic agent to a cell comprising contacting the cell with a carrier complex including a therapeutic or diagnostic agent, and a peptide-based nanofiber precursor.